Platelet aggregation-IN-3

Platelet aggregation-IN-3 (Compound 5) acts as a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. This compound can inhibit platelet aggregation induced by ADP and collagen, and it also modulates tumor cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is a promising candidate for anti-platelet therapy in cardiovascular disease and the prevention of cancer-associated thrombosis and tumor metastasis.